

Engagement Assurance Committee Cover Sheet

Item 3 Enclosure C

Title:	SEL Overprescribing project : patient engagement
Meeting Date:	26th September 2023
Author:	Lelly Oboh Lead Pharmacist Overprescribing, SEL ICS
Executive Lead:	Senior responsible officers <ul style="list-style-type: none"> Vanessa Burgess, Chief Pharmacist, Director Medicines and Long-Term Conditions, SEL ICS Toby Garrood, Joint Medical Director SEL ICS

Purpose of paper:	<p>To give an overview of how we are tackling overprescribing in SEL and provide assurance that we are engaging with the public (patients and communities, particularly those experiencing inequalities) to deliver the objectives of the project and SEL ICS</p> <ol style="list-style-type: none"> 1. In a timely way at the earliest opportunity 2. In a meaningful and appropriate way 3. Listened to views from diverse communities including those experiencing health inequalities and people with relevant lived experience 4. Considered insight and views and demonstrated how these have influenced decision making (<i>partially</i>) 5. Provided feedback to those who have given their views (<i>partially</i>) 	Update / Information	x
		Discussion	x
		Decision	
Summary of main points:	<p>The SEL overprescribing project seeks to address the complex, interdependent, multiple factors and weakness in our prescribing systems, as well as change the existing culture that creates overprescribing. It is part of a 3-year national program to tackle overprescribing https://www.gov.uk/government/publications/national-overprescribing-review-report</p> <p>Engaging with patients (their carers) and the public is key to delivering the project to improve outcomes</p> <p>Key points covered by the paper</p> <ul style="list-style-type: none"> What overprescribing is What problem we are trying to solve Reasons for overprescribing, SEL plan to tackle them and why patients/ public should be involved How we are engaging with patients and public 		

	<ul style="list-style-type: none"> Emerging themes from the engagement How engagement will inform the project and next steps 			
Potential Conflicts of Interest	None to declare			
Relevant to the following Boroughs	Bexley	x	Bromley	x
	Greenwich	x	Lambeth	x
	Lewisham	x	Southwark	x
	Equality Impact	Evidence of higher prevalence of overprescribing in certain population groups - older people, higher deprivation, Asian & Black ethnicities (national report and local data)		
	Financial Impact	Funding for the Overprescribing lead pharmacist post Oct 2022-Mar 2024		
Other Engagement	Public Engagement	<p>Mainly collaborating with the SEL patient engagement lead and team : Let's Talk SEL webpage, overprescribing webinar, patient survey, chat forum and community groups outreach</p> <p>Others include Public Health Lambeth, Health Innovation Network (HIN) AHSN polypharmacy program public campaign, Opioid QI Collaborative and Experienced Based Co-design project</p>		
	Other Committee Discussion/Engagement	<ul style="list-style-type: none"> The SEL Overprescribing Working Group (OPWG) has representatives from all parts of the system including Public health, Acute, Mental Health and Community Trusts, PCNs, SEL Personalised care, Patient engagement, Local Care Partnerships Medicines Optimisation Teams, Health Innovation Network (HIN), Kings College London SEL Integrated Medicines Optimisation Committee (IMOC) (plan approved) SEL Integrated Pharmacy Stakeholder Group (IPSG) SEL Clinical and Care Professional Committee Lambeth Together Medicines and Clinical Pathways Group (MCLiP) 		
Recommendation:	The EAC is asked to note the actions taken and give constructive feedback and suggestions on how best to continue to engage with the public to deliver the project objectives			